Just some facts. Back in Oct '17, Baker Young interviewed DXB...

Just some facts.

Back in Oct '17, Baker Young interviewed DXB Mgmt and set the target sp range from $0.62-1.49
link: http://dimerix.com/wp-content/uploads/BY-DXB-Research-Report-Oct-Initiation-of-Coverage-BUY.pdf

"We initiate coverage of Dimerix with a BUY recommendation and we value Dimerix at $0.68 per share, which is derived from using a probability weighted DCF methodology (Low Case $0.62 & High Case $1.49) based on successful Phase 2b trials and an expected big pharma licence agreement in the range of US$300-500m. Our target price of $0.68 per share sits in the lower end of our valuation range, which leaves us scope to increase this depending on what is revealed from the sub-group data and Phase 2b trial design and therefore affecting our trial success probability weighting."

A previous coverage from NDF, I think, gave a target pre-consolidation 0f 4+cents (0.80 cents post-consolidation).

A lot more ducks have been lined up since Oct '17.

That's why I think the sp should be 40-50 cents (conservative).

If the sp is still 50 cents in 2 years time, post phase 2b results (assuming 'really exciting' results) then Westar Capital would have failed as well as DXB Mgmt.

Lastly, my question is why are Westar chosen? The Perth address is just a post box really. The real office is in Melbourne.

I would have chosen a financial backer in Melb?

IMO / DYOR

cheers